ClinicalTrials.gg
Active, not recruitingNCT06798727Updated Feb 7, 2025

Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control

A Phase 2 interventional study of SMUP-IA-01(low-dose) and SMUP-IA-01(mid-dose) in Knee Osteoarthritis, sponsored by Medipost Co Ltd.. Active, not recruiting at 5 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by Medipost Co Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Mar 2023, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of — 13 open to participants now, 21 under way, 4 of them phase 3. Osteoarthritis, Knee · Korea, Republic of.

Enrollment
55th of 85
84 · median 124
Started
2023
with 4 others
Phase 2
14 of 96
1 open now
Primary completion
2027-03
later than 14 of 20 live
Registered
86th of 96
by date
Lead sponsor
4 of 96
Medipost Co Ltd.

Among the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, this one is the 55th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 14 of the 20 other live ones, and was the 86th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Osteoarthritis, Knee with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.

Read the detailed description

The subjects will be followed up at 12-month, 24-month, 36-month, 48-month and 60-month after the initial administration of SMUP-IA-01.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • human umbilical cord blood derived mesenchymal stem cells
  • hUC-MSCs
  • Knee Osteoarthritis
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who completed the safety and explore efficacy evaluations in SMUP-IA-01 Phase II clinical trial.
  2. Subject who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Subject who were not enrolled in phase II clinical trial of SMUP-IA-01 for assessing safety and explore efficacy.
  2. Other subjects, excluding those listed above, who were deemed unsuitable by the PI
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    SMUP-IA-01(low-dose)

    A single knee administration of SMUP-IA-01 (low-dose, 4.0 x 10\^6 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(low-dose)

  • Experimental
    SMUP-IA-01(mid-dose)

    A single knee administration of SMUP-IA-01 (mid-dose, 1.0 x 10\^7 cells/2mL) (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)

    Biological: SMUP-IA-01(mid-dose)

  • Active comparator
    High Hyal Plus Inj.

    A single knee administration of High Hyal Plus Inj.(1% Sodium Hyaluronate 20mg/2ml)

    Drug: High Hyal Plus

Interventions

  • BiologicalSMUP-IA-01(low-dose)

    A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

    Also known as: Human umbilical cord blood-derived mesenchymal stem cells

  • BiologicalSMUP-IA-01(mid-dose)

    A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

    Also known as: Human umbilical cord blood-derived mesenchymal stem cells

  • DrugHigh Hyal Plus

    A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)

06

What researchers measure

Primary outcomes

  1. Change of total score in WOMAC (Western Ontario and McMaster University)

    Comparing WOMAC total score changes with baseline scores of SMUP-IA-01 phase I trial and scores of f/u study at 12 months, 24 months, 36 months, 48 months and 60months after treatment (score range 0-96, higher score represent worse symptoms).

    Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment

Secondary outcomes

  1. Change of score in WOMAC three subscales (Pain, stiffness, physical function) aginst MP-SMUP-IA-01-P02's baseline.

    The WOMAC measures five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68).

    Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment

  2. Change of score in 100 mm VAS (Visual Analogue Scale)

    The score ranges from "0" or no pain to "100" very severe pain

    Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment

  3. Change of score in IKDC(International Knee Documentation Committee)

    The scores for each category are summed up and divided into 87, which is the maximum score possible, and then is evaluated by converting it into a scale of 100 points. Higher score indicates better function and less symptoms for the knee.

    Time frame: Time Frame: Month 12, 24, 36, 48 and 60 after treatment

  4. Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)

    For structural and tissue evaluation of knee, MRI image of detailed knee parts are graded from min. 0 to max. 6. Lower number indicate normal status

    Time frame: Time Frame: Month 12 and 24 after treatment

  5. Change in K&L(Kellgren-Lawrence) grade

    The K \& L grade is 0 to 4 Grade, which means that the higher the grade, the greater the joint damage and the stenosis of the joint

    Time frame: Time Frame: Month 12, 24 and 60 after treatment

  6. Change in joint space width

    Evaluation of disease progression in target knee as ascertained by change from baseline in joint space width (JSW) determined using radiography

    Time frame: Time Frame: Month 12, 24 and 60 after treatment

  7. Change in mechanical axis, anatomical axis

    The degree of deformation of the lower half of the body is measured by measuring the angles of the mechanical axis and the anatomical axis with respect to the vertical axis. Mechanical axis: A line connecting the femoral head center point and the ankle joint center point. Anatomical axis: The middiaphyseal line of the femur and tibia

    Time frame: Time Frame: Month 12, 24 and 60 after treatment

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2027, 48 months after the start.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 48 months is above that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartActual
Mar 20, 2023
Primary completionEst.
Mar 20, 2027
CompletionEst.
Nov 30, 2027
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06798727
Lead sponsor
Medipost Co Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Mar 20, 2023
Primary completion
Mar 20, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Feb 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion